Depression and anxiety affect a third or more of people with Parkinson's disease and stem from the disease's effect on dopamine, serotonin and norepinephrine circuits, not only the stress of diagnosis. Treatment uses SSRIs or SNRIs chosen to avoid interactions with MAO-B inhibitors, pramipexole where mood and motor needs align, and CBT. Most patients improve within six to ten weeks.
Stedfast Psychiatry treats the mood and anxiety symptoms of Parkinson's disease in partnership with your neurologist or movement disorder specialist. We choose antidepressants that do not worsen movement and that are compatible with Parkinson's medications, we recognize when anxiety is actually a wearing-off phenomenon that needs a neurology adjustment rather than a psychiatric drug, and we use psychotherapy adapted for the realities of a progressive illness. We see patients in our Florida and South Carolina offices, by telehealth, and on site in facilities through our Stedfast Living program. We accept Medicare.
Symptoms of Parkinson's mood
- Persistent low mood, loss of interest or tearfulness, often without obvious sadness in the face because of reduced facial expression
- Anxiety or panic that rises as a levodopa dose wears off and eases after the next dose
- Apathy: loss of motivation and initiative that family members may mistake for laziness or depression
- Fatigue, slowed thinking and difficulty concentrating beyond what the motor symptoms explain
- Insomnia, vivid dreams or acting out dreams during sleep
- Social withdrawal, often tied to embarrassment about tremor, speech or eating in public
- Irritability or pessimism about the future
- Visual hallucinations or suspicion, usually later in the illness or with medication changes
Causes and risk factors
Mood symptoms in Parkinson's disease are part of the disease biology. The same degenerative process that depletes dopamine in the movement circuits also damages serotonin-producing cells in the raphe nuclei and norepinephrine-producing cells in the locus coeruleus, often before motor symptoms appear. That is why depression and anxiety frequently precede diagnosis by years, why they do not track neatly with how severe the tremor is, and why they respond to medications that act on those systems. Dopamine loss itself produces apathy and the reduced capacity for pleasure that overlaps with depression.
On top of the biology sit the psychological and practical realities: a progressive diagnosis, loss of driving and work, changing roles in a marriage, visible symptoms in public, and sleep disruption from the disease and its treatments. Parkinson's medications contribute in both directions. Levodopa wearing off produces predictable anxiety, panic and low mood in the off periods, and dopamine agonists can cause impulse control problems, hallucinations and, when withdrawn, a withdrawal syndrome with severe anxiety and dysphoria. Deep brain stimulation can improve motor symptoms while occasionally unmasking apathy or depression.
A systematic review found clinically significant depressive symptoms in about 35 percent of people with Parkinson's disease, with major depression in roughly 17 percent and minor depression or dysthymia in most of the rest.
Source: Reijnders et al., Movement Disorders, 2008
Anxiety disorders affect an estimated 31 percent of people with Parkinson's disease, more than twice the rate in the general older population.
Source: Broen et al., Movement Disorders, 2016
In the SAD-PD randomized trial, both paroxetine and venlafaxine XR significantly improved depression in Parkinson's disease over 12 weeks without worsening motor function.
Source: Richard et al., Neurology, 2012
In a 12-week randomized placebo-controlled trial, pramipexole reduced depressive symptoms in patients with Parkinson's disease, an effect only partly explained by motor improvement.
Source: Barone et al., Lancet Neurology, 2010
How we diagnose it at Stedfast Psychiatry
Diagnosing depression in Parkinson's disease takes care because the disease mimics it. Reduced facial expression, soft voice, slowed movement, fatigue, poor sleep and weight loss are all features of Parkinson's itself. We rely on the symptoms that are specific to depression: persistent low mood, loss of interest and pleasure, guilt, hopelessness and thoughts of death. We use the Geriatric Depression Scale and the PHQ-9, which perform well in Parkinson's populations, the GAD-7 for anxiety, and the Apathy Scale to separate apathy from depression, because the two call for different treatment.
We take a detailed timeline of symptoms against the medication schedule to identify anxiety and dysphoria that cluster in off periods, since those respond to a neurology adjustment rather than an antidepressant. We ask about impulse control behaviors such as gambling, shopping, binge eating and hypersexuality, which affect a meaningful share of patients on dopamine agonists and are often hidden out of shame. We screen cognition with the MoCA, ask about hallucinations and REM sleep behavior disorder, review thyroid function and B12, and request your neurologist's records so we understand the motor stage and the full medication list, including any MAO-B inhibitor.
Treatment options
Medication management
Antidepressants work in Parkinson's disease and do not worsen motor function when chosen well. SSRIs and SNRIs are first-line. In the SAD-PD trial, both paroxetine and venlafaxine XR improved depression over twelve weeks without worsening movement scores, and we more commonly use sertraline or escitalopram for their cleaner interaction profiles. Venlafaxine or duloxetine suit patients with prominent anxiety or pain. The key interaction to manage is with MAO-B inhibitors, which many Parkinson's patients take: selegiline, rasagiline and safinamide carry labeling cautions about serotonin syndrome when combined with serotonergic antidepressants. At the usual doses the risk is low and the combination is widely used, but we confirm the dose, avoid high-dose SSRIs and avoid serotonergic additions such as tramadol, meperidine, linezolid and St. John's wort, and we coordinate with the neurologist before starting. Nortriptyline, a tricyclic with good evidence in Parkinson's depression, is an alternative when SSRIs fail, though its anticholinergic effects require care in older patients and those with orthostatic hypotension or cognitive change. Pramipexole, a dopamine agonist used for motor symptoms, showed a direct antidepressant effect in a randomized trial, and when a patient needs more motor coverage anyway, we discuss with the neurologist whether optimizing pramipexole can serve both goals; we also watch for impulse control disorders, sleepiness and hallucinations, which limit its use. Bupropion is useful for apathy and fatigue. When hallucinations or delusions need treatment, we avoid standard antipsychotics, which block dopamine and worsen movement, and use pimavanserin, which is FDA-approved for Parkinson's disease psychosis, or low-dose quetiapine. Benzodiazepines are used sparingly because of falls and confusion.
Psychotherapy
Cognitive behavioral therapy adapted for Parkinson's disease has shown benefit for depression and anxiety in controlled trials, including when delivered by telephone or video, which suits patients for whom travel is difficult. Therapy addresses the specific thoughts that drive mood in a progressive illness, builds activity around good times of day, treats social anxiety about symptoms, involves the care partner, and provides a place to process grief about losses as they come. Mindfulness-based approaches and structured exercise programs have supporting evidence for mood and may modestly help motor function. We also work with care partners, whose own depression rates are high.
Interventional options
For depression that persists after adequate medication trials, Deep TMS at our Palm Beach Gardens office is an FDA-cleared option with no drug interactions. Several studies have reported mood benefit from TMS in Parkinson's disease, and some have reported modest motor improvement, though motor treatment is not an FDA-cleared indication. Medicare covers TMS for treatment-resistant depression. Electroconvulsive therapy has a long record of improving both depression and, temporarily, motor symptoms in Parkinson's and is appropriate for severe cases through hospital-based programs.
What to expect
The first visit is a 45 to 60 minute evaluation, in person, by video or on site in a facility. We ask you to bring your complete medication list with the times you take each dose, your neurologist's contact information, and, if possible, your care partner. We map your mood and anxiety against your medication schedule, screen for apathy, impulse control problems, cognition and sleep, and leave you with a plan that typically includes one carefully chosen antidepressant, a therapy referral and a note to your neurologist about any timing or dose issues we identified. Follow-up at two to four weeks checks tolerability and blood pressure, then every four to eight weeks until remission. Telehealth works well for most follow-ups, and we communicate with your neurology team so that changes on either side are known to both.
When to seek help
Seek evaluation if low mood, loss of interest, anxiety or panic has lasted more than two weeks, if you are withdrawing from people and activities you can still physically do, if anxiety tied to medication wear-off is controlling your day, or if a care partner has noticed a change in motivation or outlook. New hallucinations, confusion or impulsive behaviors such as gambling or compulsive spending need prompt attention. Depression in Parkinson's disease raises suicide risk, and suicidal thoughts are never a normal part of the illness. If you have thoughts of ending your life, call or text 988, the Suicide and Crisis Lifeline, or go to the nearest emergency room.
Non-motor symptoms: the other half of Parkinson's disease
Parkinson's disease affects far more than movement. Depression, anxiety, apathy, sleep disorders, cognitive change, fatigue, pain, constipation and autonomic problems are grouped as non-motor symptoms, and surveys of patients consistently rank them as having a larger effect on quality of life than tremor or stiffness. They are also the symptoms least likely to be raised in a neurology visit focused on motor adjustment. A psychiatric provider who understands Parkinson's disease adds a second set of eyes for exactly these problems and can take the time a movement visit does not allow.
Anxiety in Parkinson's disease
Anxiety takes several forms in this illness. Generalized worry and social anxiety about visible symptoms are common and respond to the standard combination of an SSRI or SNRI and CBT. Panic attacks are frequent and, in a large share of patients, are tied to off periods when levodopa levels fall; they come with sweating, internal tremor, shortness of breath and a feeling of dread, and the first-line treatment is adjusting the Parkinson's regimen. A third form, fear of falling, drives social withdrawal and inactivity, which worsen both mood and motor function, and it is best treated with physical therapy and graded exposure alongside psychological support. Separating these forms is the core of good anxiety treatment in Parkinson's disease.
Impulse control disorders and dopamine agonist withdrawal
Dopamine agonists such as pramipexole and ropinirole cause impulse control disorders, including pathological gambling, compulsive shopping, binge eating and hypersexuality, in roughly one in six patients who take them. These behaviors are often hidden from family and physicians until finances or relationships are damaged, and patients rarely connect them to the medication. We ask about them directly at every visit. Treatment is to reduce or stop the agonist in coordination with neurology, but withdrawal must be gradual: a dopamine agonist withdrawal syndrome of severe anxiety, panic, depression, insomnia and craving can occur and can be mistaken for a primary psychiatric relapse. We manage the psychiatric side of that transition.
Sleep, dreams and hallucinations
REM sleep behavior disorder, in which the person acts out dreams by shouting, punching or kicking, affects about half of people with Parkinson's disease and may precede motor symptoms by a decade. It is treatable with melatonin or low-dose clonazepam and should be reported, both for bed partner safety and because it worsens daytime mood. Insomnia, fragmented sleep and daytime sleepiness are nearly universal, driven by the disease, nocturnal stiffness, nocturia and medications. Vivid dreams and visual hallucinations often begin as benign experiences and are managed by medication review before any antipsychotic is considered. Sleep improvement reliably improves depression and anxiety, so it is part of every plan we write.
Cognitive change and the long view
Mild cognitive impairment affects a sizable share of people with Parkinson's disease, and dementia can develop in later stages. Depression and anxiety worsen cognitive performance and are the reversible contributors, which is one reason to treat them early. When cognitive decline is established, antidepressant choice shifts further toward agents without anticholinergic effects, cholinesterase inhibitors such as rivastigmine may help both cognition and hallucinations, and our Stedfast Living program provides continuity for patients who move into assisted living or skilled nursing. The prognosis for mood symptoms in Parkinson's disease is good: most patients respond to treatment, and improved mood often brings better engagement in exercise, therapy and social life, which in turn supports motor function. The illness is progressive; the depression and anxiety do not have to be.
Frequently asked questions
Can I take an antidepressant with rasagiline or selegiline?
Usually, yes, with coordination. MAO-B inhibitors carry a labeled caution about serotonin syndrome when combined with SSRIs and SNRIs, but at standard Parkinson's doses the enzyme selectivity makes the risk low, and large surveys of movement disorder specialists show the combination is used routinely. We keep antidepressant doses moderate, avoid adding other serotonergic drugs such as tramadol or St. John's wort, teach you the warning signs of serotonin syndrome, and confirm the plan with your neurologist. Selegiline at higher doses loses selectivity and needs more caution.
My anxiety comes in waves that match my medication schedule. Is that psychiatric?
Probably not primarily. Anxiety, panic, sweating and a sense of dread that arrive as a levodopa dose wears off and resolve after the next dose are a non-motor wearing-off symptom, and the treatment is to adjust the Parkinson's regimen so the off periods shrink. We map your symptoms against your dose times, send that information to your neurologist, and treat residual anxiety with an antidepressant or CBT only if it persists once the regimen is optimized.
Is it depression or apathy?
They overlap but differ. Apathy is loss of motivation and initiative without sadness; the person is content to sit, does not feel distressed about it and does not report hopelessness. Depression includes low mood, guilt, pessimism and often anxiety. Apathy is common in Parkinson's disease, relates to dopamine loss, and responds poorly to SSRIs, which can even worsen it; it responds better to structured activity, exercise, dopaminergic optimization and sometimes bupropion or a cholinesterase inhibitor. We use the Apathy Scale to tell them apart.
Will antidepressants make my tremor or stiffness worse?
Generally no. The SAD-PD trial showed no worsening of motor scores with paroxetine or venlafaxine, and clinical experience with sertraline and escitalopram is similar. A small number of patients notice a slight increase in tremor on SSRIs, which usually settles or responds to a change of agent. Mirtazapine can help sleep and appetite and may slightly improve tremor. Medications we avoid because they do worsen movement are standard antipsychotics, metoclopramide and prochlorperazine.
Can pramipexole treat my depression?
It can help. In a randomized trial, pramipexole improved depressive symptoms in Parkinson's patients beyond what motor improvement explained, likely because it acts on dopamine receptors in reward circuits. If your neurologist is already considering pramipexole for motor symptoms, that mood benefit is a point in its favor. It is not a standalone antidepressant, and it carries risks of sleepiness, hallucinations, leg swelling and impulse control disorders such as gambling, which we screen for at every visit.
What about hallucinations?
Visual hallucinations affect a large share of people with Parkinson's disease over time, often starting as a sense of presence or fleeting shapes in the periphery. When they are mild and not distressing, education and reducing evening medications may be enough. When treatment is needed, we avoid typical antipsychotics and risperidone or olanzapine, which worsen movement, and use pimavanserin, FDA-approved for Parkinson's disease psychosis, or low-dose quetiapine. We also check for infection, dehydration and new medications that may have triggered them.
Does Medicare cover this and can it be done by telehealth?
Medicare Part B covers psychiatric evaluation, medication management and psychotherapy, including by video, and Stedfast Psychiatry accepts Medicare and most Medicare Advantage plans. Telehealth is well suited to Parkinson's care, since travel, parking and waiting rooms are hard when mobility is limited, and CBT delivered by video has been shown to work for Parkinson's depression. We ask for an in-person visit at the start when we can, and we see facility residents on site through our Stedfast Living program.
My spouse has Parkinson's and I am exhausted. Is there help for me?
Yes. Care partners of people with Parkinson's disease have high rates of depression, anxiety and burnout, and the patient's mood tends to improve when the care partner's does. Our therapists offer individual counseling for care partners, education about non-motor symptoms, and help setting limits and finding respite. We also point families to the Parkinson's Foundation helpline and local support groups. Looking after yourself is part of looking after your spouse.
Where to get treatment for depression and anxiety in Parkinson's disease
Evaluation and treatment for depression and anxiety in Parkinson's disease is available at every Stedfast Psychiatry office and by video across Florida and South Carolina.
Related conditions
If you are thinking about harming yourself, call or text 988 now, or go to the nearest emergency room. This page is educational and does not replace an evaluation. Clinical content reviewed by Dr. David Husted, board-certified psychiatrist.